TP53 and liver cancer: Investigate whether CDC7 inhibition can induce senescence in TP53‐mutant HCC cellsIdentify and exploit vulnerabilities in senescent liver cancer cells to enhance therapeutic efficacy.Assess the effect of combining CDC7 inhibition with mTOR inhibition or sertraline to promote senolysis and tumor suppression